Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Biochemical Reagents > Erdafitinib for Sale > Erdafitinib 99% high quality manufacture in China Dideu group
Erdafitinib 99% high quality manufacture in China Dideu group buy - large image1
Erdafitinib 99% high quality manufacture in China Dideu group buy - image1
Erdafitinib 99% high quality manufacture in China Dideu group buy - image2
Erdafitinib 99% high quality manufacture in China Dideu group buy - image3
Erdafitinib 99% high quality manufacture in China Dideu group buy - image4
Erdafitinib 99% high quality manufacture in China Dideu group buy - image5
Erdafitinib 99% high quality manufacture in China Dideu group buy - image6

Erdafitinib 99% high quality manufacture in China Dideu group

TDS 546 Inquiries

Unit Price: Get Latest Price
CAS No.:

1346242-81-6

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Shanghai

Brand:

Dideu

Packaging:

100g/Bottle

Price valid (until):

2026-08-01

Company Type:
Manufactory
Location:
China
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
7 days
Qualification:
Main Products:

Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

  • Product Description

  • Seller Information

  • Inquiry History

  • Description

    High quality Erdafitinib producer

    Shop 1,3-Propanediol PDO-Detailed Image 1

    Erdafitinib is a kinase inhibitor targeting FGFR and is used to treat adult patients with locally advanced or metastatic urothelial carcinoma. It is applicable for patients with locally advanced or metastatic urothelial carcinoma who experience disease progression during or after platinum-based chemotherapy. These patients have FGFR3 or FGFR2 gene mutations, including those who have received neoadjuvant or adjuvant platinum-based chemotherapy within 12 months.

    Bioactivity Erdafitinib (JNJ-42756493) is an effective, selective, and orally bioactive pan-fibroblast growth factor receptor FGFR inhibitor with potential anti-tumor activity. Erdafitinib can also bind to RET (c-RET), CSF-1R, PDGFR-α/PDGFR-β, FLT4, Kit (c-Kit), and VEGFR-2 and can induce cell apoptosis.

    In vitro studies have shown that JNJ-42756493 is an effective, orally active pan-FGFR tyrosine kinase inhibitor with IC50 values for all members of the FGFR family (FGFR1-4) within the low-molar range, while its activity against VEGFR is minimal. In vitro, treatment with JNJ-42756493 leads to reduced cell proliferation, increased apoptotic death, and decreased cell survival. In vivo studies showed that treatment with JNJ-42756493 delayed the growth of NCI-H716 tumors, and the tumor volume increased when the drug treatment was withdrawn. JNJ-42756493 has good drug-like properties and is widely distributed in lung, liver, and kidney tissues. At effective doses, JNJ-42756493 is well tolerated, has dose-dependent anti-tumor activity, and has drug-regulating effects on components of FGFR and its downstream pathways in tumors.

    Shop 1,3-Propanediol PDO-Detailed Image 2

     

     

    Item

    Specification

    Appearance

    Yellow soild powder
    Water Content,%
    0.046
    Total Impurity,%
    0.30
    Single Impurity,%
    0.21
    Purity,%
    99.70
    Shop 1,3-Propanediol PDO-Detailed Image 3

    Our normal packaging is 10mg/bottle;15mg/bottle,etc.We can make different specifications according to customer requirements。

    The packaging can be customized. the shipping term can be by sea, by air, and sample or small quantity can be shipped by DHL, FEDEX, EMS and TNT.

    Shop 1,3-Propanediol PDO-Detailed Image 4
    Shop 1,3-Propanediol PDO-Detailed Image 5

    a) Free sample can be supplied.

    b) Guide our clients by professional knowledge and teach them how to use our product after sales.

    c) Accept SGS, BV any other third-party inspection before loading.

    d) High quality best price Guaranteed.

    Shop 1,3-Propanediol PDO-Detailed Image 6
    Shop 1,3-Propanediol PDO-Detailed Image 7

    Why do you choose Dideu as your partner?

    A) High quality can be guaranteed. Dideu since 1975 are reputed chemical manufacturer and are Certified by ISO 9001;2015 and have GMP certification.Free sample can be arranged before shipment and SGS,BV and other third party inspection company are accepted before loading.For regular customers, we accept L/C 180 Days, D/P, D/A payment term. If there is any quality problem after goods arrive. Dideu will do fully payment refund.

    B) Best price can be guaranteed. As Dideu are integrated pharmaceuticals and chemicals producer, the production cost can be controlled and price will be definitely more competitive than China trading companies.

    C) Professional engineers from Dideu will give professional usage guide and services after sales.

    D)Dideu work 7×24 hours and your request will be processed by our professional staff in different shift period.

    Shop 1,3-Propanediol PDO-Detailed Image 8
    Shop 1,3-Propanediol PDO-Detailed Image 9
    Shop 1,3-Propanediol PDO-Detailed Image 10
    Shop 1,3-Propanediol PDO-Detailed Image 11
    Shop 1,3-Propanediol PDO-Detailed Image 12

    Dideu is one of the largest producer for general chemical, pharmaceutical, nutrition additive, natural extracts, agrochemical and Daily-Use Chemical in China and is headquartered in Shaanxi, China. The Dideu Group comprises subsidiaries and joint ventures in more than 10 countries and operates six integrated production sites and 21 other production sites in Europe, Asia, Australia, Americas and Africa. Its headquarters is located in Xi’An,China. Dideu has customers in over 200 countries and supplies products to a wide variety of industries.


    At the end of 2014, the company employed more than 13000 people. In 2014, Dideu Group posted sales of 30 billion and income from operations before special items of about 7.5 billion. The company is currently expanding its international activities with a particular focus on Asia countries. Between 1990 and 2005, the company invested 5.2 billion in Asia, for example in sites near Guangxi,Yunnan, Sichuan, Shaanxi China, Mangalore in India,Bangkok, Thailand,Hanoi, Vietnam etc.


    Dideu Consist Of Five Industry Chains:


    1. 1)Pharmaceutical Industries
    2. 2)Nutrition Additive Industries
    3. 3)Daily-Use Chemical Products Industries & Agrochemicals
    4. 4)Environmental Friendly Chemical And Chemurgy Industries
    5. 5)Petrochemical Industries
    6. 6)General Chemical Industry


    At Dideu, we redefine chemistry to make the world better - and have been doing so for 75 years. As one of the world's leading chemical company, we combine economic success with environmental protection and social responsibility. Through science and innovation we enable our customers in nearly every industry to meet the current and future needs of society.


    At Dideu, we create chemistry for a sustainable future with science for a better life. Dideu is a Life Science company with a long and glorious history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. The growing and increasingly aging world population requires improved medical care and an adequate supply of food. Dideu is improving people's quality of life by preventing, alleviating and treating diseases. And we are helping to provide a reliable supply of high quality food, feed and plant based raw materials. We develop new molecules for use in innovative products and solutions to improve health. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms. Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing humankind, and by doing this exceptionally well we aim to strengthen the company's earning power.


    We are committed to operating sustainably and addressing our social and ethical responsibilities as a corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees with a passion for innovation enjoy excellent development opportunities at Dideu. Exclusive Focus on the Life Science Businesses Following the economic and legal independence of our former Material Science subgroup. Dideu has charted the course for its successful development as a Life Science company. Our Life Science businesses hold leading positions in innovation driven growth markets. Together they make up a strong, attractive and balanced portfolio that is resistant to fluctuations in demand and to potential risks.The previous structure comprising a strategic management holding company and operational subgroups has thus been replaced by an integrated organization under the umbrella of the strong Dideu brand. The company's operations are managed in three divisions Pharmaceuticals, Consumer Health and Crop Science and the Animal Health business unit. The business continues to be supported by the corporate functions, Dideu Business Services and the service company Current, while Technology Services is being integrated into Dideu Group, forming the Engineering and Technology function.

    ECHEMI Editorial Reference
    Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy. Erdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions. Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.|Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor receptors (FGFR) 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.|Erdafitinib is an orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.

    Certificates

    Basic Info
    Product Name:

    Erdafitinib

    Other Name:

    1,2-Ethanediamine,N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;Erdafitinib;JNJ 42756493;Balversa;1620332-47-9

    CAS No.:

    1346242-81-6

    Molecular Formula:

    C25H30N6O2

    InChIKeys:

    InChIKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N

    Molecular Weight:

    446.54

    Exact Mass:

    446.54

    UNII:

    890E37NHMV

    NCI Thesaurus Code:

    C103273

    ATC Code:

    L - Antineoplastic and immunomodulating agents

    Categories:

    Biochemical Reagents

    Characteristics
    PSA:

    77.3

    XLogP3:

    3.2

    Density:

    1.2±0.1 g/cm3

    Flash Point:

    354.4±31.5 °C

    Refractive Index:

    1.618

    Water Solubility:

    <1 mg/mL

    Research
    Class:

    Pan-FGFR tyrosine kinase inhibitor (FGFR1-4); antineoplastic (ATC L01EN01)

    Status:

    Approved (FDA accelerated approval 2019-04-12; converted to regular approval 2024-01-19; EMA approval 2024-08)

    Mechanism:

    Erdafitinib is an orally bioavailable, functionally selective small-molecule inhibitor of fibroblast growth factor receptors 1-4 (FGFR1-4). It inhibits FGFR tyrosine kinase activity (IC50 1.2-5.7 nM), blocking downstream RAS-MAPK/ERK and PI3K-AKT signaling that drives proliferation and survival of tumor cells harboring activating FGFR alterations (mutations, amplifications, or fusions). Rapid lysosomal uptake contributes to prolonged inhibition of FGFR signaling.

    EC50 (Fgfr1 Ic50):

    1.2 nM

    EC50 (Fgfr3 Ic50):

    3.0 nM

    EC50 (Fgfr2 Ic50):

    2.5 nM

    EC50 (Fgfr4 Ic50):

    5.7 nM

    EC50 (Vegfr2 Ic50):

    36.8 nM (approximately 30-fold selectivity vs FGFR1)

    Source:

    Perera TPS, et al. Mol Cancer Ther. 2017;16(6):1010-1020.DOI

    Clinical Development:

    NCT02365597; NCT03390504

    FDA:

    Balversa (approved 2019-04-12)

    References
    ChEMBL:

    CHEMBL3545376

    DrugBank:

    DB12147

    KEGG DRUG:

    D10927

    PubChem:

    PubChem

    Disclaimer:

    Erdafitinib (Balversa) is a prescription medicine approved by the US FDA and the EMA for specific oncology indications. ECHEMI lists this product for industrial sourcing and supply-chain reference only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or a substitute for approved therapy. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

    Hazard Identification

    Classification of the substance or mixture

    Acute toxicity - Category 4, Oral

    Skin sensitization, Sub-category 1B

    Serious eye damage, Category 1

    Reproductive toxicity, Category 2

    Specific target organ toxicity – repeated exposure, Category 1

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Danger

    Hazard statement(s)

    H302 Harmful if swallowed

    H317 May cause an allergic skin reaction

    H318 Causes serious eye damage

    H361 Suspected of damaging fertility or the unborn child

    H372 Causes damage to organs through prolonged or repeated exposure

    Precautionary statement(s)
    Prevention

    P264 Wash ... thoroughly after handling.

    P270 Do not eat, drink or smoke when using this product.

    P261 Avoid breathing dust/fume/gas/mist/vapours/spray.

    P272 Contaminated work clothing should not be allowed out of the workplace.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    P203 Obtain, read and follow all safety instructions before use.

    P260 Do not breathe dust/fume/gas/mist/vapours/spray.

    Response

    P301+P317 IF SWALLOWED: Get medical help.

    P330 Rinse mouth.

    P302+P352 IF ON SKIN: Wash with plenty of water/...

    P333+P317 If skin irritation or rash occurs: Get medical help.

    P321 Specific treatment (see ... on this label).

    P362+P364 Take off contaminated clothing and wash it before reuse.

    P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

    P317 Get medical help.

    P318 IF exposed or concerned, get medical advice.

    P319 Get medical help if you feel unwell.

    Storage

    P405 Store locked up.

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

    Location:

    https://www.dideu.com/en/

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    7 days

    Total Annual Revenue:

    Above $100 million

    Total Employees:

    Above 1000

    Year of Establishment:

    2016

    Company Certificates
    • Shaanxi Dideu Medichem Co. LtdISO Certificate ISO Certificate
    • Shaanxi Dideu Medichem Co. LtdREACH REACH
    Company Profile
    ">Company Profile
  • Inquiry History
    546 Inquiries
    Country Product Purchase Quantity Date Posted
    Germany

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Aug 25, 2026
    Vietnam

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Aug 18, 2026
    United States

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Jul 26, 2026
    Australia

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Aug 14, 2026
    Poland

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Jul 28, 2026
    Canada

    Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6

    1 G Sep 15, 2026
    United Kingdom

    Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6

    1 MT Sep 4, 2026
    Canada

    Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6

    500 MG Sep 1, 2026
    Canada

    Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6

    500 MG Aug 25, 2026
    United States

    Factory Supply Erdafitinib CAS 1346242-81-6 99% High Purity FGFR Inhibitor API Powder

    1 G Sep 3, 2026
    United States

    Hot Selling ERDAFITINIB 1346242-81-6 Factory Supply Raw Materials High Qulity Wholesale price

    3 MT Jul 5, 2026
    Canada

    Erdafitinib

    1 G Oct 12, 2026
    Australia

    Erdafitinib

    500 MG Sep 16, 2026
    Australia

    Erdafitinib

    1 G Jul 18, 2026
    Germany

    Erdafitinib

    500 MG Jul 28, 2026
    Cyprus

    Erdafitinib

    1 G Jul 22, 2026
    Bulgaria

    Erdafitinib

    500 MG Jun 18, 2026
    Spain

    Erdafitinib

    1 G Sep 25, 2026
    Spain

    Erdafitinib

    1  Sep 14, 2026
    Germany

    Erdafitinib

    5 G Sep 17, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.